282 related articles for article (PubMed ID: 32998289)
1. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.
Chang YC; Chen MH; Yeh CN; Hsiao M
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32998289
[TBL] [Abstract][Full Text] [Related]
2. Current omics-based biomarkers for cholangiocarcinoma.
Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
[No Abstract] [Full Text] [Related]
3. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ; Shan YS; Hung WC; Chen LT
Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
[TBL] [Abstract][Full Text] [Related]
4. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
5. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.
Zhou Z; Ma J
Cancer Biomark; 2019; 24(2):173-181. PubMed ID: 30594918
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
7. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker.
Chiang KC; Yeh TS; Wu RC; Pang JS; Cheng CT; Wang SY; Juang HH; Yeh CN
Sci Rep; 2016 Oct; 6():36138. PubMed ID: 27782193
[TBL] [Abstract][Full Text] [Related]
8. Role of noncoding RNAs in cholangiocarcinoma (Review).
Lv Y; Wang Z; Zhao K; Zhang G; Huang S; Zhao Y
Int J Oncol; 2020 Jul; 57(1):7-20. PubMed ID: 32319584
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches in search for biomarkers of cholangiocarcinoma.
Mocan LP; Ilieș M; Melincovici CS; Spârchez M; Crăciun R; Nenu I; Horhat A; Tefas C; Spârchez Z; Iuga CA; Mocan T; Mihu CM
World J Gastroenterol; 2022 Apr; 28(15):1508-1525. PubMed ID: 35582128
[TBL] [Abstract][Full Text] [Related]
10. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
[TBL] [Abstract][Full Text] [Related]
11. The expression of gastrointestinal differentiation markers in extrahepatic cholangiocarcinoma: clinicopathological significance based on tumor location.
Ishida K; Osakabe M; Eizuka M; Tai S; Sugimoto R; Fujita Y; Katagiri H; Takahara T; Uesugi N; Nitta H; Sasaki A; Sugai T
Hum Pathol; 2019 Oct; 92():91-100. PubMed ID: 31401234
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1.
Sinniah RS; Shapses MS; Ahmed MU; Babiker H; Chandana SR
Expert Opin Investig Drugs; 2021 Oct; 30(10):1047-1056. PubMed ID: 34579607
[TBL] [Abstract][Full Text] [Related]
13. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
14. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
15. Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and
Yao Y; Jiao D; Liu Z; Chen J; Zhou X; Li Z; Li J; Han X
Biomed Res Int; 2020; 2020():5976127. PubMed ID: 33490245
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic biomarkers in cholangiocarcinoma.
Macias RIR; Kornek M; Rodrigues PM; Paiva NA; Castro RE; Urban S; Pereira SP; Cadamuro M; Rupp C; Loosen SH; Luedde T; Banales JM
Liver Int; 2019 May; 39 Suppl 1():108-122. PubMed ID: 30843325
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis of intrahepatic cholangiocarcinoma.
Andersen JB
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):101-13. PubMed ID: 25174625
[TBL] [Abstract][Full Text] [Related]
18. Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.
Guedj N; Vaquero J; Clapéron A; Mergey M; Chrétien Y; Paradis V; Fouassier L
Histopathology; 2016 Aug; 69(2):211-21. PubMed ID: 26791814
[TBL] [Abstract][Full Text] [Related]
19. Clinical correlation of cadherin-17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma.
Zheng BH; Shen S; Wong KF; Gong ZJ; Sun WT; Ni XJ; Wang JW; Hu MY; Liu H; Ni XL; Liu HB; Luk JM; Suo T
J Surg Oncol; 2021 Apr; 123(5):1253-1262. PubMed ID: 33524213
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma.
Hu ZG; Zheng CW; Su HZ; Zeng YL; Lin CJ; Guo ZY; Zhong FD; Yuan GD; He SQ
J Cell Biochem; 2019 Jun; 120(6):9964-9978. PubMed ID: 30582202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
